Core Insights - The article highlights the significant application value of recombinant human hyaluronidase in the medical field, particularly in subcutaneous administration combined with antibodies, offering multiple advantages over traditional intravenous delivery [1][7]. Market Overview - The global recombinant human hyaluronidase market is projected to reach USD 799 million by 2024, with a year-on-year growth of 18.4% [1][7]. - North America maintains a leading position in the market due to its mature healthcare system, while the Asia-Pacific region, including China, shows strong growth potential [1][7]. Industry Policies - The Chinese government has implemented various policies to support the development of the pharmaceutical manufacturing industry, including the recombinant human hyaluronidase sector, creating a favorable policy environment for growth [4][5]. Industry Chain - The upstream of the recombinant human hyaluronidase industry includes gene components, host cells, culture media, consumables, and production equipment. The midstream focuses on R&D, production, quality control, and registration, while the downstream encompasses applications in assisted reproduction, antibody drug development, aesthetic medicine, gene therapy, and tumor treatment [5][6]. Development Status - The recombinant human hyaluronidase industry in China is entering a rapid growth phase, with a projected market size of CNY 186 million by 2024, reflecting a year-on-year increase of 143.8%, significantly outpacing the global average [7][8]. - The industry is driven by national innovation policies and increasing clinical demand, with expanding applications in medical aesthetics and tumor treatment [7][8]. Competitive Landscape - Several recombinant human hyaluronidase products have been approved globally, including Halozyme Therapeutics' rHuPH20 and Alteogen's Tergase. Shanghai Baijia Pharmaceutical Co., Ltd. has established a first-mover advantage in China with its KJ017 product, which is currently in the NDA registration stage [9][10]. - Baijia Pharmaceutical's revenue from recombinant human hyaluronidase is expected to reach CNY 3.111 million in 2024, marking a year-on-year growth of 681.7% [9][10]. Development Trends - Future innovations in recombinant human hyaluronidase will focus on optimizing gene engineering technology to enhance product purity and activity, as well as developing long-acting formulations and composite preparations [11][12]. - The application scenarios for recombinant human hyaluronidase are expected to diversify, expanding into targeted tumor therapy, assisted reproduction, and orthopedic disease treatment [11][12]. - Domestic companies are anticipated to accelerate the process of replacing international giants in high-end product areas, supported by policy backing and enhanced R&D capabilities [12].